TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8214547

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intramuscular pethidine 75 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study: 2443151

Group type: EXPERIMENTAL
Intervention: Radiation therapy combined with bleomycin
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Radiation therapy combined with a retinoid
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Surgery after irradiation
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Preoperative therapy
Number of subjects: 110
Study: 28712024

Group type: EXPERIMENTAL
Intervention: Knee hyperextension during functional activities in ACL‐R knees.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Maximum knee extension angle during running in ACL‐R knees.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Side-to-side difference (SSD) of internal tibial rotation during walking and running in ACL‐R knees.
Number of subjects: 42
Study: 26315564

Group type: EXPERIMENTAL
Intervention: Osteotome sinus floor elevation (OSFE) without grafting material
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Osteotome sinus floor elevation (OSFE) with deproteinized bovine bone (DBB)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Osteotome sinus floor elevation (OSFE) with β‐tricalcium phosphate (β‐TCP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Osteotome sinus floor elevation (OSFE) with β‐TCP and DBB combination
Number of subjects: 45
Study: 25012498

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system inhibition (RASI) with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
Number of subjects: 1873
Study: 22321388

Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Mesh group
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both groups (subgroup analysis of women with a partner)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Male sexual functioning
Number of subjects: 125
Study: 19776651

Group type: EXPERIMENTAL
Intervention: PCT-guided treatment
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard treatment based on conventional laboratory parameters
Number of subjects: 121
Study: 18714171

Group type: EXPERIMENTAL
Intervention: Prednisone plus gefitinib (pG)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Prednisone plus placebo (ppl)
Number of subjects: 82
Study: 17194239

Group type: EXPERIMENTAL
Intervention: 60% 1RM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 80% 1RM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 90% 1RM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bench press at 90% 1RM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 16
Study: 14578079

Group type: EXPERIMENTAL
Intervention: Highly demanding secondary task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less demanding secondary task
Number of subjects: 0
Study: 10787068

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 10 mg IM
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 20 mg IM
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 40 mg IM
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Chlorpheniramine maleate 20 mg IM)
Number of subjects: 60
Study: 8955971

Group type: EXPERIMENTAL
Intervention: Genius
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thermopit
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Quickthermo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thermoscan
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mon‐a‐Therm thermocouples
Number of subjects: 50
Study: 1471304

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (historic control group)
Number of subjects: 10
Study: 6148960

Group type: EXPERIMENTAL
Intervention: xamoterol 0.1 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: saline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: xamoterol
Number of subjects: 8
Study: 30374040

Group type: EXPERIMENTAL
Intervention: Automated Office Blood Pressure (AOBP) using Omron HEM-907
Number of subjects: 108

Group type: COMPARATOR
Intervention: Observed Office Blood Pressure (OOBP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Awake Ambulatory Blood Pressure (AABP)
Number of subjects: 108
Study: 30656171

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg per night and nocturnal splint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nerve and tendon gliding exercises and nocturnal splint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg per night, exercises, and nocturnal splint
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nocturnal splint (control group)
Number of subjects: 0
Study: 26973734

Group type: EXPERIMENTAL
Intervention: Nuclear stress test (NucST)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Non-nuclear stress test (Non-NucST)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Algorithm introduction
Number of subjects: 240
Study: 25305703

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800 mg/day initiated within 24 hours after PCI
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no EPA treatment)
Number of subjects: 115
Study: 23057726

Group type: EXPERIMENTAL
Intervention: Tobacco-sponsored smoking cessation ads
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Public health ads with tobacco company identification
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Ambiguous ad content
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Direct ad content about health consequences of smoking
Number of subjects: 270
Study: 20579863

Group type: EXPERIMENTAL
Intervention: 150 mg Pycnogenol a day
Number of subjects: 98

Group type: COMPARATOR
Intervention: Compression stockings only
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Combination of Pycnogenol and elastic stockings
Number of subjects: 98
Study: 18042893

Group type: EXPERIMENTAL
Intervention: Femoral nerve blockade
Number of subjects: 62

Group type: COMPARATOR
Intervention: IV analgesia with metamizol
Number of subjects: 62
Study: 16534182

Group type: EXPERIMENTAL
Intervention: Pitavastatin (1 mg/day, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 30
Study: 12855831

Group type: EXPERIMENTAL
Intervention: Younger subjects (mean age 28+/‐8 years)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Older subjects (mean age 69+/‐10 years)
Number of subjects: 50
Study: 10559077

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Borg scale
Number of subjects: 23

Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 11361492

Group type: EXPERIMENTAL
Intervention: On-site social work activities (postintervention)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Preintervention group
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Initial postintervention group
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Long-term postintervention group
Number of subjects: 594
Study: 1854026

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 5 micrograms/mL epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2% 2-chloroprocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: lidocaine
Number of subjects: 30
Study: 6337670

Group type: EXPERIMENTAL
Intervention: Anal dilator (no. 2) twice daily for 3 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Anaesthetic jelly without dilator for 3 weeks
Number of subjects: 66
Study: 31261584

Group type: EXPERIMENTAL
Intervention: High CRP levels
Number of subjects: 192

Group type: COMPARATOR
Intervention: Low CRP levels
Number of subjects: 192
Study: 28137918

Group type: EXPERIMENTAL
Intervention: Telecoaching intervention group (IG)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 343
Study: 26852743

Group type: EXPERIMENTAL
Intervention: Medical management (ongoing therapy)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Medical management with treatment crossover to endoscopic sinus surgery (ESS)
Number of subjects: 75
Study: 25086763

Group type: EXPERIMENTAL
Intervention: Individual cognitive behavior therapy (CBT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Group cognitive behavior therapy (CBT)
Number of subjects: 54
Study: 22001151

Group type: EXPERIMENTAL
Intervention: Topical ciclosporin A (CsA) 2%
Number of subjects: 366

Group type: COMPARATOR
Intervention: Dexamethasone 0.1%
Number of subjects: 366
Study: 19178574

Group type: EXPERIMENTAL
Intervention: AGTR1 1166A > C and AGT Met235Thr polymorphisms
Number of subjects: 25000
Study: 17952523

Group type: EXPERIMENTAL
Intervention: Cervical hand‐sewn anastomosis (CHS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intrathoracic stapled anastomosis (ITS)
Number of subjects: 32
Study: 15642666

Group type: COMPARATOR
Intervention: sTfR in normal subjects
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: sTfR in HH patients
Number of subjects: 87
Study: 11728763

Group type: EXPERIMENTAL
Intervention: Benzyl alcohol with epinephrine, 1:100,000 (BA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Lidocaine with epinephrine, 1:100,000 (LID)
Number of subjects: 52
Study: 9387965

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing after exposure to mouldy hay in patients with farmer's lung
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cardiopulmonary exercise testing in asymptomatic farmers
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison of patients with farmer's lung to asymptomatic farmers
Number of subjects: 36
Study: 7940137

Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 44
Study: 3764628

Group type: EXPERIMENTAL
Intervention: 250 mg ciprofloxacin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 100 mg ciprofloxacin
Number of subjects: 50
Study: 29504810

Group type: EXPERIMENTAL
Intervention: 0.016-inch TiNbTaZr archwires
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.016-inch NiTi archwires
Number of subjects: 28
Study: 27722222

Group type: EXPERIMENTAL
Intervention: Immediate implants
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Immediate-delayed implants (6 weeks)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Delayed implants (4 months)
Number of subjects: 210
Study: 24977750

Group type: EXPERIMENTAL
Intervention: Cryopreserved red blood cells (CPRBC)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Liquid preserved packed red blood cells (LPRBC)
Number of subjects: 57
Study: 23484300

Group type: EXPERIMENTAL
Intervention: Video education plus traditional patient education (TPE)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Leaflet education plus traditional patient education (TPE)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Traditional patient education (TPE) alone
Number of subjects: 133
Study: 21426445

Group type: EXPERIMENTAL
Intervention: N8
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advate(®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N8 and Advate(®)
Number of subjects: 0
Study: 18503141

Group type: COMPARATOR
Intervention: 20 mg tadalafil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 mg nitrendipine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil + 5 mg nitrendipine
Number of subjects: 8

Group type: COMPARATOR
Intervention: All protocols
Number of subjects: 8
Study: 16580059

Group type: EXPERIMENTAL
Intervention: Skinsafe intervention
Number of subjects: 589
Study: 12702127

Group type: EXPERIMENTAL
Intervention: Trizivir (abacavir-lamivudine-zidovudine combination tablet) administered twice daily
Number of subjects: 209

Group type: COMPARATOR
Intervention: Continued treatment (two nucleoside reverse transcriptase inhibitors plus a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor or three nucleoside reverse transcriptase inhibitors)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Trizivir (abacavir-lamivudine-zidovudine combination tablet)
Number of subjects: 209
Study: 10752915

Group type: EXPERIMENTAL
Intervention: Flunisolide administered via AeroChamber, 750 microg (3 puffs), twice daily
Number of subjects: 176

Group type: COMPARATOR
Intervention: Budesonide administered via Turbuhaler, 600 microg (3 puffs), twice daily
Number of subjects: 176
Study: 9373479

Group type: EXPERIMENTAL
Intervention: Topical levobunolol HCl 0.5% (LEV)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Artificial tears (TEAR)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Topical levobunolol HCl 0.5% (LEV) vs Artificial tears (TEAR)
Number of subjects: 15
Study: 1530166

Group type: EXPERIMENTAL
Intervention: Clonidine (2.5 micrograms/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 60
Study: 6754844

Group type: EXPERIMENTAL
Intervention: Intervention group (screening and examination, barium meal examination for those with possible or probable peptic ulcer)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 199
Study: 31825472

Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP) with active tDCS
Number of subjects: 68

Group type: COMPARATOR
Intervention: Mindfulness-based relapse prevention (MBRP) with sham tDCS
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 68
Study: 30336170

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxygen face mask
Number of subjects: 20
Study: 27943153

Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg BID days 1-28 plus Bevacizumab 2.5 mg/kg every other week (MTD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg BID (phase I)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg BID plus Bevacizumab 2.5 mg/kg (phase II)
Number of subjects: 24
Study: 29798325

Group type: EXPERIMENTAL
Intervention: Yanhouqing buccal tablets (high dose)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Yanhouqing buccal tablets (low dose)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: All groups (Yanhouqing buccal tablets and placebo)
Number of subjects: 288
Study: 24619016

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg (80 mg/day) administered twice daily (4 and 3 hours prior to each radiotherapy fraction)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo administered twice daily (4 and 3 hours prior to each radiotherapy fraction)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 22951179

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Regional epidural anesthesia
Number of subjects: 50
Study: 19741581

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day, group A, N. 22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (group B, N. 22)
Number of subjects: 44
Study: 17455838

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (Zymar)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Vigamox)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (Zymar) and Moxifloxacin (Vigamox)
Number of subjects: 35
Study: 16418625

Group type: EXPERIMENTAL
Intervention: Patients with WAD
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 29
Study: 14633533

Group type: EXPERIMENTAL
Intervention: Esmolol 50 mg and nicardipine 1 mg, followed by an esmolol infusion 5 microg x kg(‐1) x min(‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Esmolol 50 mg, followed by an esmolol infusion 5 microg x kg(‐1) x min(‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Esmolol infusion as an adjunct to desflurane
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal saline 5 mL and 1 mL, followed by a saline infusion at a rate of 0.005 mL x kg(‐1) x min(‐1)
Number of subjects: 45
Study: 10540300

Group type: EXPERIMENTAL
Intervention: Regimen I: 300 mg dihydroartemisinin + 750 mg mefloquine concurrently
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Regimen II: 300 mg dihydroartemisinin + 750 mg mefloquine 24 h later
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Regimen III: 300 mg dihydroartemisinin + 750 mg mefloquine at 24 h and 500 mg at 30 h
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Regimen IV: 300 mg dihydroartemisinin + 750 mg mefloquine at 0 h and 500 mg at 24 h
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: High-dose mefloquine regimens (III and IV)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Patients who vomited within the first hour of mefloquine administration
Number of subjects: 207
Study: 8913125

Group type: EXPERIMENTAL
Intervention: Lowering of the venous closing pressure within four months of onset of central retinal vein obstruction
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lowering of the venous closing pressure thereafter
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 50
Study: 1929765

Group type: EXPERIMENTAL
Intervention: Transference interpretations provided by therapists
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High proportions of transference interpretations
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 64
Study: 7037162

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600 mg/m2 IV plus DTIC 600 mg/m2 IV day 1 (CD)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 400 mg/m2 IV, DTIC 400 mg/m2 IV, and piperazinedione 4 mg/m2 IV on day 1 (PCD)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Both treatment programs (CD and PCD)
Number of subjects: 195
Study: 31665314

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months in year 1
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once-weekly in year 2
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Denosumab followed by Alendronate
Number of subjects: 126
Study: 29703649

Group type: EXPERIMENTAL
Intervention: Index cholecystectomy (IC) performed within 48 hours
Number of subjects: 66

Group type: COMPARATOR
Intervention: Delayed cholecystectomy (DC)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Index cholecystectomy (IC)
Number of subjects: 66
Study: 28215430

Group type: EXPERIMENTAL
Intervention: Child-Only Intervention
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Child + Caregiver Intervention
Number of subjects: 790
Study: 25754525

Group type: EXPERIMENTAL
Intervention: Early endoscopic intervention with preventive pancreatic stenting
Number of subjects: 230

Group type: COMPARATOR
Intervention: Early endoscopic intervention without pancreatic stenting
Number of subjects: 230

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 230
Study: 23812892

Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive-behavioral therapy for adherence and depression with an alarmed pillbox
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 20875810

Group type: EXPERIMENTAL
Intervention: Simvastatin (40mg/day)
Number of subjects: 102
Study: 18505580

Group type: EXPERIMENTAL
Intervention: Self-selected velocity walking in individuals with CFS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Relatively slow velocity walking (0.45 ms‐1) in individuals with CFS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Relatively fast velocity walking (1.30 +/‐ 0.24 ms‐1) in individuals with CFS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Self-selected velocity walking in matched controls
Number of subjects: 24
Study: 16151062

Group type: EXPERIMENTAL
Intervention: Intercostal approach
Number of subjects: 70

Group type: COMPARATOR
Intervention: Subcostal approach
Number of subjects: 70
Study: 12975222

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (ChEIs)
Number of subjects: 5159
Study: 10443750

Group type: EXPERIMENTAL
Intervention: Insulin (0.035 IU/kg i.v.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: i.v. saline (control)
Number of subjects: 20
Study: 8688258

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg kg‐1 and glycopyrronium 0.01 mg kg‐1
Number of subjects: 41

Group type: COMPARATOR
Intervention: No antagonism of mivacurium
Number of subjects: 41

Group type: COMPARATOR
Intervention: No neuromuscular blockers
Number of subjects: 41
Study: 1990899

Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms.kg‐1 infused over 3 h)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 6352035

Group type: EXPERIMENTAL
Intervention: Gentamicin-cefoxitin (G-C)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Netilmicin-cefoxitin (N-C)
Number of subjects: 37
Study: 31727409

Group type: EXPERIMENTAL
Intervention: Resmetirom 80 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 26517965

Group type: EXPERIMENTAL
Intervention: BFR-walk
Number of subjects: 7

Group type: COMPARATOR
Intervention: CON-walk
Number of subjects: 7
Study: 25559905

Group type: EXPERIMENTAL
Intervention: Progressive Plyometric Training (PPT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Non-Progressive Plyometric Training (NPPT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 24
Study: 24373006

Group type: EXPERIMENTAL
Intervention: 595-nm PDL with nonpurpuric settings (10 ms)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 595-nm PDL with purpuric settings (1.5 ms)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 26
Study: 21647559

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) - 10 min of ischemia and 10 min of reperfusion before parenchymal transection (10/10)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control - Intermittent inflow occlusion (15 min of ischemia and 5 min of reperfusion repetitively; 15/5)
Number of subjects: 32